advertisement

WGA Rescources

Abstract #47670 Published in IGR 13-4

Comparative study of the pressure lowering efficacy and variations in the ocular pulse amplitude between fixed combinations of dorzolamide/timolol and brinzolamide/timolol

Sanchez-Pulgarin M; Martinez-de-la-Casa JM; Garcia- Feijoo J; Saenz-Frances F; Santos-Bueso E; Herrero-Vanrell R; Garcia Sanchez J
Archivos de la Sociedad EspaƱola de Oftalmologia 2011; 86: 149-153


Objective: To determine possible differences in the intraocular pressure (IOP) and ocular pulse amplitude (OPA) lowering capacity of the fixed drug combinations dorzolamide/timolol and brinzolamide/timolol. Methods: In this cross-sectional study, one of the eyes of 25 healthy subjects was randomly assigned to treatment with dorzolamide/timolol and the other eye with brinzolamide/timolol. After instilling the drops, possible adverse effects (e.g., blurred vision, itching) were assessed in each eye. This assessment was repeated 30 minutes later. IOP and OPA were determined In each eye by dynamic contour tonometry at baseline and two hours following treatment. Results: Both fixed drug combinations significantly reduced IOP and OPA with no differences detected between treatment groups. Among the adverse effects recorded, itching was significantly greater in the first assessment in the eyes treated with dorzolamide/timolol (P = .011). This difference was no longer apparent in the second assessment. Conclusions: Both fixed combinations were similarly effective in reducing intraocular pressure and ocular pulse amplitude. Adverse effects related to both treatments were mild and well-tolerated, though itching occurred most frequently in the eyes treated with dorzolamide/timolol. (copyright) 2011 Published by Elsevier Espana. LA: Spanish

M. Sanchez-Pulgarin. Hospital Clinico San Carlos, Madrid, Spain. Email: m.sanchezpulgarin@gmail.com


Classification:

11.13.2 Betablocker and carbon anhydrase inhibitor (Part of: 11 Medical treatment > 11.13 Combination therapy)



Issue 13-4

Change Issue


advertisement

Oculus